Autism Spectrum Disorders (ASD) or Pervasive Developmental Disorder (PDD) defines a group of developmental disability disorders. These disorders include: Autism, Pervasive Developmental Disorder not otherwise specified (PDD-NOS), Asperger syndrome, Rett syndrome and Childhood Disintegrative Disorder (CDD). The latter two are very rare and often absent from studies, and therefore not covered by this report.
Attributes of these disorders can be grouped into three areas: communication difficulties, repetitive and stereotyped behaviour, and social impairment. ASD is collectively called a “wide-spectrum” disorder due to the wide variation of symptoms which can occur in any given patient. The nature of these symptoms and their life-long duration constitute a serious burden to both the patients and their families, often limiting career prospects and personal life success.
This report provides the current prevalent population for autism spectrum disorders across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Austria, Denmark, Sweden, Russia, Turkey, Japan, China, South Korea, Singapore, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several features of autism spectrum disorder patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of autism spectrum disorders include:
- Epilepsy (especially in ASD with intellectual disability)
- GI problems
- Restless Sleep
- Motor function / co-ordination problems
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Ability to quantify patient populations in global autism spectrum disorder market to target the development of future products, pricing strategies and launch plans.
- Further insight into the prevalence of the subdivided types of autism spectrum disorders and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding of the impact of specific co-morbid conditions on the prevalent population of autism spectrum disorder patients.
- Identification of autism spectrum disorder patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of autism spectrum disorder patients.